Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Gigantism refers to abnormally high linear growth due to excessive action of insulinlike growth factor I (IGF-I) while the epiphyseal growth plates are open during childhood. Acromegaly is the same disorder of IGF-I excess but occurs after the growth plate cartilage fuses in adulthood.
The global acromegaly and gigantism treatment market can be segmented into treatment, end users, and geographical expansion. On the basis of treatment, the market is divided into surgery, radiation therapy, and medication. The medication segment can be further divided into different drug types such as somatostatin analogs, GH receptor antagonists, dopamine agonists and others. The medication segment is expected to hold a significant market share during the forecast period due to factors such as effectiveness of drugs, noninvasive and lesser side effects than radiation therapies, and strong pipeline portfolio.
The report details the trend, potential and market size of Acromegaly and Gigantism Drugs market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Acromegaly and Gigantism Drugsmarket, defines the market attractiveness level of Acromegaly and Gigantism Drugs market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Acromegaly and Gigantism Drugs industry, describes the types of Acromegaly and Gigantism Drugs market, the applications of major players and the market size, and deeply analyzes the current situation of the global Acromegaly and Gigantism Drugs market and the development prospects and opportunities of Acromegaly and Gigantism Drugs industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Acromegaly and Gigantism Drugs market in Chapter 13.
By Player:
Ipsen
Pfizer
Novartis
By Type:
Somatostatin Analogs
GH Receptor Antagonists
Dopamine Agonists
Recombinant Human IGF-1
By End-User:
Hospitals
Clinics
Others
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Acromegaly and Gigantism Drugs Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Acromegaly and Gigantism Drugs Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Acromegaly and Gigantism Drugs Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Acromegaly and Gigantism Drugs Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Acromegaly and Gigantism Drugs Market Analysis and Outlook to 2022
-
7.1 Global Acromegaly and Gigantism Drugs Consumption (2017-2022)
-
7.2 United States Acromegaly and Gigantism Drugs Consumption (2017-2022)
-
7.3 Europe Acromegaly and Gigantism Drugs Consumption (2017-2022)
-
7.4 China Acromegaly and Gigantism Drugs Consumption (2017-2022)
-
7.5 Japan Acromegaly and Gigantism Drugs Consumption (2017-2022)
-
7.6 India Acromegaly and Gigantism Drugs Consumption (2017-2022)
-
7.7 South Korea Acromegaly and Gigantism Drugs Consumption (2017-2022)
8 Region and Country-wise Acromegaly and Gigantism Drugs Market Analysis and Outlook to 2028
-
8.1 Global Acromegaly and Gigantism Drugs Consumption Forecast (2022-2028)
-
8.2 United States Acromegaly and Gigantism Drugs Consumption Forecast (2022-2028)
-
8.3 Europe Acromegaly and Gigantism Drugs Consumption Forecast (2022-2028)
-
8.4 China Acromegaly and Gigantism Drugs Consumption Forecast (2022-2028)
-
8.5 Japan Acromegaly and Gigantism Drugs Consumption Forecast (2022-2028)
-
8.6 India Acromegaly and Gigantism Drugs Consumption Forecast (2022-2028)
-
8.7 South Korea Acromegaly and Gigantism Drugs Consumption Forecast (2022-2028)
9 Global Acromegaly and Gigantism Drugs Market Outlook by Types and Applications to 2022
-
9.1 Global Acromegaly and Gigantism Drugs Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Somatostatin Analogs Consumption and Growth Rate (2017-2022)
-
9.1.2 Global GH Receptor Antagonists Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Dopamine Agonists Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Recombinant Human IGF-1 Consumption and Growth Rate (2017-2022)
-
9.2 Global Acromegaly and Gigantism Drugs Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Others Consumption and Growth Rate (2017-2022)
10 Global Acromegaly and Gigantism Drugs Market Outlook by Types and Applications to 2028
-
10.1 Global Acromegaly and Gigantism Drugs Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Somatostatin Analogs Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global GH Receptor Antagonists Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Dopamine Agonists Consumption Forecast and Growth Rate (2022-2028)
-
10.1.4 Global Recombinant Human IGF-1 Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Acromegaly and Gigantism Drugs Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)
11 Global Acromegaly and Gigantism Drugs Import and Export Analysis (Top 5 Countries)
-
11.1 Global Acromegaly and Gigantism Drugs Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Acromegaly and Gigantism Drugs Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Acromegaly and Gigantism Drugs Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Acromegaly and Gigantism Drugs Market Competitive Analysis
-
14.1 Ipsen
-
14.1.1 Ipsen Company Details
-
14.1.2 Ipsen Acromegaly and Gigantism Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Ipsen Acromegaly and Gigantism Drugs Product and Service
-
14.2 Pfizer
-
14.2.1 Pfizer Company Details
-
14.2.2 Pfizer Acromegaly and Gigantism Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Pfizer Acromegaly and Gigantism Drugs Product and Service
-
14.3 Novartis
-
14.3.1 Novartis Company Details
-
14.3.2 Novartis Acromegaly and Gigantism Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Novartis Acromegaly and Gigantism Drugs Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Acromegaly and Gigantism Drugs
-
Figure Acromegaly and Gigantism Drugs Picture
-
Table Global Acromegaly and Gigantism Drugs Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Acromegaly and Gigantism Drugs Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Acromegaly and Gigantism Drugs Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Acromegaly and Gigantism Drugs Consumption by Country (2017-2022)
-
Figure United States Acromegaly and Gigantism Drugs Consumption and Growth Rate (2017-2022)
-
Table Europe Acromegaly and Gigantism Drugs Consumption and Growth Rate (2017-2022)
-
Figure China Acromegaly and Gigantism Drugs Consumption and Growth Rate (2017-2022)
-
Figure Japan Acromegaly and Gigantism Drugs Consumption and Growth Rate (2017-2022)
-
Figure India Acromegaly and Gigantism Drugs Consumption and Growth Rate (2017-2022)
-
Figure South Korea Acromegaly and Gigantism Drugs Consumption and Growth Rate (2017-2022)
-
Figure Global Acromegaly and Gigantism Drugs Consumption Forecast by Country (2022-2028)
-
Figure United States Acromegaly and Gigantism Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Acromegaly and Gigantism Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Acromegaly and Gigantism Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Acromegaly and Gigantism Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Acromegaly and Gigantism Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Acromegaly and Gigantism Drugs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Somatostatin Analogs Consumption and Growth Rate (2017-2022)
-
Figure Global GH Receptor Antagonists Consumption and Growth Rate (2017-2022)
-
Figure Global Dopamine Agonists Consumption and Growth Rate (2017-2022)
-
Figure Global Recombinant Human IGF-1 Consumption and Growth Rate (2017-2022)
-
Figure Global Hospitals Consumption and Growth Rate (2017-2022)
-
Figure Global Clinics Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Somatostatin Analogs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global GH Receptor Antagonists Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Dopamine Agonists Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Recombinant Human IGF-1 Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Acromegaly and Gigantism Drugs Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Acromegaly and Gigantism Drugs Export by Region (Top 5 Countries) (2017-2028)
-
Table Ipsen (Foundation Year, Company Profile and etc.)
-
Table Ipsen Acromegaly and Gigantism Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Ipsen Acromegaly and Gigantism Drugs Product and Service
-
Table Pfizer (Foundation Year, Company Profile and etc.)
-
Table Pfizer Acromegaly and Gigantism Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Acromegaly and Gigantism Drugs Product and Service
-
Table Novartis (Foundation Year, Company Profile and etc.)
-
Table Novartis Acromegaly and Gigantism Drugs Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis Acromegaly and Gigantism Drugs Product and Service
-
